期刊
DIABETES CARE
卷 32, 期 12, 页码 2263-2268出版社
AMER DIABETES ASSOC
DOI: 10.2337/dc09-0901
关键词
-
资金
- Ministry of Science, Education and Culture of Japan [20791039, 20590699]
- 2008 Japan Osteoporosis Society (JOS)
OBJECTIVE - Patients with type 2 diabetes are known to have an increased risk for fracture compared with non-type 2 diabetic control subjects, despite having higher bone mineral density (BMD). We previously showed that serum pentosidine, one of the advanced glycation end 2 products (AGES), was associated with prevalent vertebral fractures (VFs) in those with type. diabetes. The involvement of the endogenous secretory receptor for AGES (esRAGE) in VFs in those with type 2 diabetes, however, is still unknown. RESEARCH DESIGN AND METHODS - We compared parameters including esRAGE, pentosidine, and BMD in Japanese type 2 diabetic patients (137 men >50 years old and 140 postmenopausal women) with and without VFs. RESULTS - The esRAGE-to-pentosidine ratio in type 2 diabetic patients with VFs was significantly lower than in those without VFs (men: 7.1 +/- 2.8 Vs. 9.4 +/- 6.2, P = 0.013, respectively; women: 4.7 +/- 2.7 vs. 8.2 +/- 5.4, P < 0.001, respectively). Multivariate logistic regression analysis adjusted for age, BMI, A1C, serum creatinine, duration of diabetes, therapeutic agents, diabetes complications, osteoporotic risk factors, and lumbar BMD identified the serum esRAGE level and esRAGE-to-pentosidine ratio as factors associated With the presence of VFs, independent of BMD in men (odds ratio [OR] 0.46 [95% CI 0.25-0.84], P = 0.012; and OR 0.34 [0.15-0.76], P = 0.009, respectively) and in women (OR 0.32 [0.16-0.67], P = 0.002; and OR 0.14 [0.04-0.43], P = 0.001, respectively). CONCLUSIONS- These results show that serum esRAGE level and esRAGE-to-pentosidine ratio are more useful than BMD for assessing the risk of VFs in type 2 diabetic of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据